Key Events This Week
23 Mar: New 52-week low at Rs.1,743.45 amid market downturn
25 Mar: Intraday high surge of 8.03% to Rs.1,905.65
27 Mar: Week closes at Rs.1,855.25, down 2.90% on the day
Apr 10
BSE+NSE Vol: 8.29 k

RPG Life Sciences Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a modest decline in share price. This repositioning comes amid a challenging pharmaceutical sector landscape, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now presenting a more compelling investment case relative to peers and historical averages.
Read full news article
RPG Life Sciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 16 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
23 Mar: New 52-week low at Rs.1,743.45 amid market downturn
25 Mar: Intraday high surge of 8.03% to Rs.1,905.65
27 Mar: Week closes at Rs.1,855.25, down 2.90% on the day

RPG Life Sciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 16 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
The Sensex climbed 1.77% on 25 Mar 2026, yet RPG Life Sciences Ltd outpaced the broader market with an 8.03% gain, reaching an intraday high of Rs 1905.65. This 5.56 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector’s 2.54% advance signals a distinctly stock-specific rally rather than a market-wide lift.
Read full news article
RPG Life Sciences Ltd witnessed a significant intraday decline on 23 Mar 2026, touching a fresh 52-week low of Rs 1,743.45 as the stock underperformed both its sector and the broader market amid widespread selling pressure.
Read full news article
RPG Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.
Read full news article
RPG Life Sciences Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade amid evolving market dynamics. This article examines the implications of changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical averages and peer benchmarks to assess the stock’s price attractiveness.
Read full news articleCertificate in terms of Regulation 74(5) of the SEBI (DP) Regulations 2018
Newspaper Advertisement in respect to Special Window opened for lodgment of transfer and dematerialization request(s).
RPG Life Sciences Limited has informed the Exchange regarding - Second -100 Days Campaign - Saksham Niveshak
No Upcoming Board Meetings
RPG Life Sciences Ltd has declared 250% dividend, ex-date: 27 Jun 25
No Splits history available
No Bonus history available
No Rights history available